Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 57.57M | 56.60M | 62.64M | 63.70M | 66.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.57M | 56.60M | 62.64M | 63.70M | 66.38M |
| Cost of Revenue | 20.75M | 19.94M | 20.77M | 20.66M | 20.55M |
| Gross Profit | 36.82M | 36.66M | 41.87M | 43.03M | 45.83M |
| SG&A Expenses | 42.64M | 40.69M | 39.09M | 37.75M | 38.29M |
| Depreciation & Amortization | 2.49M | 2.65M | 2.81M | 3.21M | 3.68M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.89M | 63.50M | 63.05M | 62.52M | 63.85M |
| Operating Income | -8.32M | -6.90M | -413.00K | 1.18M | 2.54M |
| Income Before Tax | -14.23M | -33.67M | -24.24M | -13.28M | -13.75M |
| Income Tax Expenses | 21.00K | 447.00K | 315.00K | 32.00K | 437.00K |
| Earnings from Continuing Operations | -14.25 | -34.12 | -24.56 | -13.31 | -14.18 |
| Earnings from Discontinued Operations | -- | 62.00K | 116.00K | 239.00K | 620.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.25M | -34.06M | -24.44M | -13.07M | -13.56M |
| EBIT | -8.32M | -6.90M | -413.00K | 1.18M | 2.54M |
| EBITDA | -4.39M | -2.63M | 4.03M | 6.03M | 7.91M |
| EPS Basic | -1.38 | -4.30 | -3.11 | -1.93 | -1.90 |
| Normalized Basic EPS | -0.86 | -1.89 | -1.17 | -0.34 | -0.23 |
| EPS Diluted | -1.67 | -4.58 | -3.84 | -3.05 | -3.13 |
| Normalized Diluted EPS | -0.93 | -1.96 | -1.33 | -0.55 | -0.46 |
| Average Basic Shares Outstanding | 49.31M | 36.78M | 32.40M | 28.50M | 25.13M |
| Average Diluted Shares Outstanding | 59.35M | 46.82M | 44.51M | 42.96M | 32.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |